University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Adil Daud, MD

Adil Daud, MD

HS Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center

Cancer Center Program Memberships

Cancer Immunology

Education

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine


Professional Experience

  • 1987-1990
    Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
  • 1990-1994
    Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
  • 1994-1997
    Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
  • 1997-2000
    Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2000-2001
    Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2001-2005
    Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
  • 2006-2008
    Director, Moffitt Clinical Research Network
  • 2008-2010
    Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
  • 2010-present
    HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

Honors & Awards

  • 1986
    Honors in Pediatrics, Government Medical College, Nagpur, India
  • 2000
    Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
  • 2005-2007
    Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
  • 2007-2010
    Best Doctors in America Award, Castle Connolly

Selected Publications

  1. Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother. 2018 Mar 01; 1-5.
    View on PubMed
  2. Daud AI. Revisiting RECIST: the case of treatment beyond progression. Lancet Oncol. 2018 Feb; 19(2):157-159.
    View on PubMed
  3. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2017 Dec 28; JCO2017756270.
    View on PubMed
  4. Grob JJ, Schadendorf D, Lorigan P, Ascierto P, Larkin J, Nathan P, Robert C, Hauschild A, Weber J, Daud A, Hamid O, Dummer R, Hansson J, Hoeller C, Schachter J, Van Akkooi ACJ, Garbe C. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. Eur J Cancer. 2018 Mar; 91:168-170.
    View on PubMed
  5. Algazi AP, Esteve-Puig R, Nosrati A, Hinds B, Hobbs-Muthukumar A, Nandoskar P, Ortiz-Urda S, Chapman PB, Daud A. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018 Jan; 31(1):110-114.
    View on PubMed
  6. Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340.
    View on PubMed
  7. Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
    View on PubMed
  8. Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH, Pierce RH, Gargosky S, Daud A, Algazi A. Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy. 2017 Dec; 9(16):1309-1321.
    View on PubMed
  9. Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 11; 86:296-304.
    View on PubMed
  10. Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 Mar 01; 36(7):667-673.
    View on PubMed
  11. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Oct 21; 390(10105):1853-1862.
    View on PubMed
  12. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Pampaloni M, Alvarado MD, Rosenblum MD, Daud AI. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 07 20; 2(14).
    View on PubMed
  13. Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018 Feb 01; 36(4):383-390.
    View on PubMed
  14. Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 01; 28(6):1380-1387.
    View on PubMed
  15. Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 Jul; 22(7):823-833.
    View on PubMed
  16. Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, Khurana N, Nosrati A, Krummel MF, Tucker A, Sosa EV, Sanchez PJ, Banayan N, Osorio JC, Nguyen-Kim DL, Chang J, Shintaku IP, Boasberg PD, Taylor EJ, Munster PN, Algazi AP, Chmielowski B, Dummer R, Grogan TR, Elashoff D, Hwang J, Goldinger SM, Garon EB, Pierce RH, Daud A. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Cancer Immunol Res. 2017 May; 5(5):417-424.
    View on PubMed
  17. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TDL, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Apr 25; 116(9):1141-1147.
    View on PubMed
  18. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440.
    View on PubMed
  19. Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017 01 04; 10(1):3.
    View on PubMed
  20. Loo K, Daud AI. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017 Jan/Feb; 23(1):3-9.
    View on PubMed

Go to UCSF Profiles, powered by CTSI